MedTrace Logo

Study of CBP-4888 in Healthy, Non-Pregnant Female Subjects

NCT05881993 · Status: COMPLETED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2025-09-26

No results posted yet for this study

Summary

This is a Phase I, first-in-human, single-center, randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of ascending doses of CBP-4888.

Conditions

  • Healthy Volunteer Study

Interventions

DRUG

CBP-4888

siRNA therapeutic

OTHER

Placebo

Normal Saline

Sponsors & Collaborators

  • Comanche Biopharma

    lead INDUSTRY

Principal Investigators

  • Allison August, MD · Chief Medical Officer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2023-05-22
Primary Completion
2024-05-22
Completion
2024-05-22
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05881993 on ClinicalTrials.gov